<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1566">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140772</url>
  </required_header>
  <id_info>
    <org_study_id>19/5/2019 ANET4</org_study_id>
    <nct_id>NCT05140772</nct_id>
  </id_info>
  <brief_title>Glutamine Effects in Burn Patients</brief_title>
  <official_title>Evaluations the Effect of Parenteral Glutamine on Reducing Infection Morbidity in Burn Patients in ICU. A Randomized Controlled Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the effect of parenteral glutamine supplementation on&#xD;
      infection in burn patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improvements in prevention and management, burn injury continues to represent a major&#xD;
      threat to the health and welfare of people worldwide in all age groups. Even with early&#xD;
      surgical intervention and aggressive antibiotic therapy, infectious complications are a major&#xD;
      cause of death in severe burn injury, accounting for 75% of all deaths occurring after&#xD;
      initial resuscitation.&#xD;
&#xD;
      It is proposed that one source of these infections is a translocation of gram-negative&#xD;
      bacteria from the gut. However, this mechanism of bacterial translocation through the gut&#xD;
      wall remains a controversial mechanism of infection in humans. In animal studies, it has been&#xD;
      demonstrated that glutamine supplementation can decrease gut-derived bacterial translocation&#xD;
      and improve outcomes from burn injury.&#xD;
&#xD;
      Whether this holds true in humans has to be evaluated by additional studies. A recent study&#xD;
      concluded that glutamine supplementation reduces gram-negative bacteremia in burned patients&#xD;
      but viewed itself as preliminary and suggested that more clinical trials are warranted to&#xD;
      corroborate the study outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>wound culture test</measure>
    <time_frame>on 1,5,10 and 15 days after ICU admission</time_frame>
    <description>whether +ve or -ve test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin level</measure>
    <time_frame>on 1,5,10 and 15 days after ICU admission</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>on 1,5,10 and 15 days after ICU admission</time_frame>
    <description>mg/litre</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient were received 0.5gm/kg/day IV glutamine infusion (dipeptiven 100ml contains 20 g N(2)-L-alanyl-L-glutamine (= 8.20 g L-alanine, 13.46 g L-glutamine) Water for Injections).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received an equivalent volume of normal saline daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptiven</intervention_name>
    <description>IV administration daily for 7 days</description>
    <arm_group_label>group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal Saline</intervention_name>
    <description>IV administration daily for 7 days</description>
    <arm_group_label>group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-50 years.&#xD;
&#xD;
          -  Total burn surface area of 20% - 60%.&#xD;
&#xD;
          -  Expected length of stay in ICU &gt; 48 hr.&#xD;
&#xD;
          -  Admission within 72 hrs of burn injury.&#xD;
&#xD;
          -  Any thermal injury such as flame burns. Scald burns and contact burns.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Burn patients with hepatic failure.&#xD;
&#xD;
          -  Burn patient with Severe renal failure (glomerular filtration rate (eGFR &lt;50 ml/min).&#xD;
&#xD;
          -  Patients with inborn errors of amino-acid metabolism (e.g., phenylketonuria).&#xD;
&#xD;
          -  Burn patients with pre-existing severe cardiac, pulmonary diseases.&#xD;
&#xD;
          -  Burn patients with diabetes mellitus or cancer.&#xD;
&#xD;
          -  Patients with metabolic acidosis (pH&lt;7.35).&#xD;
&#xD;
          -  Electric burns.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ashraf Magdy Eskandr</name>
      <address>
        <city>Shibeen Elkoom</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>ashraf magdy eskandr</investigator_full_name>
    <investigator_title>assistant professor of anesthesia</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available with after the end of the study when requested</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

